Epizyme reported $-28524000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Abbott ABT:US $ 2985M 750M
Agios Pharmaceuticals AGIO:US $ -95.35M 3.32M
Amarin AMRN:US $ -36.84M 9.31M
Amgen AMGN:US $ 3004M 337M
Avrobio Inc AVRO:US $ -27420000 1.6M
Biogen BIIB:US $ 1075.7M 401M
Bluebird Bio BLUE:US $ -99.42M 19.92M
Cerulean Pharma CERU:US $ -8.4M 1.14M
Daiichi Sankyo 4568:JP Y 49252M 84953M
Eisai 4523:JP Y 17237M 28829M
Epizyme EPZM:US $ -28.52M 21.1M
Exelixis EXEL:US $ 88.48M 0.75M
Gilead Sciences GILD:US $ 2585M 837M
GlaxoSmithKline GSK:LN 2447M 673M
Glaxosmithkline GSK:US $ 2447M 673M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Macrogenics MGNX:US $ -38931000 24.79M
Mirati Therapeutics MRTX:US $ -176.51M 7.08M
Novartis NVS:US $ 4660M 108M
Novartis NOVN:VX SF 4660M 108M
Pfizer PFE:US $ 12921M 1739M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Seattle Genetics SGEN:US $ -115.89M 0.06M
Vertex Pharmaceuticals VRTX:US $ 1156.6M 87.3M
Xencor XNCR:US $ -25.78M 54.42M